The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
 
Jessica Lin
Honoraria - Answers in CME; Clinical Care Options; Curio Science; HMP Education; Medscape; OncLive; PeerView; TotalCME
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Bristol Myers Squibb; CLaiM Therapeutics; Daiichi Sankyo/Astra Zeneca; Elevation Oncology; Ellipses Pharma; Genentech; Gilead Sciences; Hyku Biosciences; Janssen; Lilly; Merus; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Nuvation Bio; Nuvectis Pharma; Pfizer; Regeneron; Roche/Genentech; Takeda; Triana; Turning Point Therapeutics; Yuhan
Research Funding - Bayer (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb; Elevation Oncology (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Summit Therapeutics; Sutro Biopharma; Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Merus; Pfizer; Takeda
Other Relationship - Bristol Myers Squibb (Inst); Genentech (Inst); Nuvalent, Inc. (Inst)
 
Enriqueta Felip
Honoraria - Amgen; Daiichi Sankyo Europe GmbH; Gilead Sciences; Janssen / Johnson & Johnson; Lilly; MSD; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Genentech/Roche; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Pfizer; PharmaMar; Pierre Fabre; Regeneron; Seagen; Tubulis GmbH
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - J INTS BIO; KANAPH Therapeutics Inc.
Consulting or Advisory Role - Cyrus therapeutixs; J Ints Bio; KANAPH Theripeutic Inc
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; ESMO; Guardant Health; IASLC; Korean Cancer Association; Korean Cancer Study Group; Korean Society of Medical Onoclogy; Korean Society of Thyroid-Head and Neck Surgery; MSD; Novartis; Pfizer; Roche; The Chinese Thoracic Oncology Society; Zai Lab
Research Funding - CJ bioscience; Cyrus Therapeutics; Dong-A ST; ImmuneOncia; J Ints Bio; Johnson & Johnson; Ligachem bioscience; MSD; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Benjamin Besse
Honoraria - Abbvie (Inst); Helios Medical Communications Ltd (Inst); OSE Immunotherapeutics (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); OncoC4 (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); SERVIER (Inst); Tubulis GmbH (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Prelude Therapeutics (Inst); Sanofi (Inst)
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; emd serono; Jazz Pharmaceuticals; Merck; novartis; nuvation bio; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Lorenza Landi
Consulting or Advisory Role - AbbVie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson; MSD; Nuvalent, Inc.; Pfizer; Roche
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Johnson & Johnson; Lilly; MSD; Novartis; Pfizer; Roche; Thermo Fisher Scientific
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Beone; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Chiara Bennati
No Relationships to Disclose
 
Aurélie Swalduz
Honoraria - Amgen; AZD; Johnson & Johnson/Janssen; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Daiichi Sankyo Europe GmbH; Janssen; Roche
Travel, Accommodations, Expenses - Janssen; MSD Oncology; Roche
 
Sanjay Popat
Consulting or Advisory Role - Amgen; Anheart Therapeutics; Arcus Biosciences; AstraZeneca; Bayer; Bicycle Therapeutics; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Ellipses Pharma; Erasca, Inc; Genmab; Gilead Sciences; GlaxoSmithKline; Guardant Health; IO Biotech; Janssen; Lilly; Merck KGaA; MSD; Nuvalent, Inc.; Pfizer; Pfizer; PharmaMar; Pierre Fabre; Pierre Fabre; Roche; SERVIER; Summit Therapeutics; Taiho Oncology; Takeda
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Roche/Genentech
 
Misako Nagasaka
Stock and Other Ownership Interests - MBrace Therapeutics
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb USA; Caris Life Sciences; Daiichi Sankyo; Genentech; Johnson and Johnson; Lilly; Pfizer; Regeneron; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Johnson and Johnson; Pfizer; Takeda
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Joshua Reuss
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Gilead Sciences; Janssen; Lilly; Merck; Nuvation Bio; Pfizer; Regeneron; Roche Molecular Diagnostics; Signatera; Summit Therapeutics
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); DualityBio (Inst); Genentech/Roche (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Regeneron (Inst); Revolution Medicines (Inst); Verastem (Inst)
 
Christina Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Lilly; Natera; Nuvalent, Inc.; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blossom Hills (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Summit Therapeutics (Inst); Systimmune (Inst); TP Therapeutics (Inst)
 
Julien Mazieres
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Pfizer; Pierre Fabre; Revolution Medicines; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; MSD; Pfizer
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeOne Medicines (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Summit Therapeutics (Inst); Zai Lab (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); BlossomHill Therapeutics (Inst); Boehringer Ingelheim (Inst); Boundless Bio (Inst); Bristol-Myers Squibb (Inst); Carisma Therapeutics (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Modex Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); RasCal (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Shanghai Junshi BioSciences (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Systimmune (Inst); Taiho Oncology (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Adrianus Johannes De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)
 
Ji-Youn Han
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Janssen; Merck; Novartis
Research Funding - Pfizer; Roche
 
Malinda Itchins
Honoraria - AstraZeneca; MSD Oncology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; Janssen Oncology; Medison; MSD Oncology; Pfizer; Roche
Research Funding - Pfizer (Inst)
 
Viola Zhu
Employment - Nuvalent, Inc.
Stock and Other Ownership Interests - Nuvalent, Inc.
Patents, Royalties, Other Intellectual Property - Nuvalent, Inc.
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; AstraZeneca; Bristol Myers Squibb Foundation; Clinical Care Options/NCCN; i3 Health; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; OncLive/MJH Life Sciences; PER; Remedica; Research to Practice
Consulting or Advisory Role - Anheart Therapeutics; Axis Pharma; Bayer; Boundless Bio; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Med Learning; Medscape; Melendi; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; PeerView; Repare Therapeutics; touchIME; Treeline Biosciences; Zymeworks
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Anheart Therapeutics (Inst); Bayer (Inst); Boundless Bio (Inst); Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Triana (Inst)